HAE Haemonetics Corporation
USHealthcareAs of 2026-07-10 12:04
Why HAE matters now
Haemonetics Corporation (HAE) is a US stock in Healthcare. The latest InvestLog snapshot shows $75.94 with +1.25% on the session and $3.45B in market capitalization; recent performance reads 1-month +30.47% and YTD -7.46%.
The latest financial table shown here is Q4 2026, with revenue of $346.4M, net income of $-20.1M, and EPS of $-0.44. Investors can compare that operating picture with valuation signals such as P/E 15.29 and FCF yield 7.7%.
The latest indexable market news headline is "Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $85.00; recent insider activity includes Miller Laurie A. filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
15.29
PEG
0.44
P/B
4.31
P/S
2.53
EV/EBITDA
15.52
DCF Value
$237.38
FCF Yield
7.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.3%
Operating Margin
18.2%
Net Margin
7.3%
ROE
11.3%
ROA
4.1%
ROIC
8.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2026 | $346.4M | $-20.1M | $-0.44 |
| FY 2026 | $1.33B | $97.3M | $2.05 |
| Q3 2026 | $339.0M | $44.7M | $0.95 |
| Q2 2026 | $327.3M | $38.7M | $0.81 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$80.33
Target (Median)
$85.00
Target Range
$67.00 - $89.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
0.54
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.